biomarker test News
-
OncoDNA and Synlab Partner to Facilitate Access to Comprehensive Biomarker Testing for Cancer Therapy Selection in Germany
SYNLAB LABORATORIES TO PERFORM ONCODEEP® BIOMARKER TEST TO HELP DOCTORS DECIDE ON THE MOST EFFECTIVE TREATMENT FOR THEIR CANCER PATIENTS ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, ANNOUNCED TODAY A PARTNERSHIP WITH SYNLAB, EUROPE’S LEADING CLINICAL LABORATORY AND MEDICAL DIAGNOSTIC SERVICES PROVIDER. ...
By OncoDNA S.A.
-
OncoDNA and Bergonié Institute to test the clinical utility of blood-and tissue-based biomarker tests in oncology
OncoDNA, a genomic and theranostic company specializing in precision medicine, and Bergonié Institute, a non-profit private hospital entirely devoted to fighting cancer, today announced a new clinical trial to evaluate the use of comprehensive biomarker testing and liquid biopsy in 700 patients diagnosed with an advanced metastatic cancer. The Appolo study will recruit patients from 6 ...
By OncoDNA S.A.
-
Berkshire and Surrey Pathology Services & ONCODNA announce formation of a national tissue collection centre that will facilitate private NGS testing across the UK
DR CHENG BOON, ONCOLOGIST IN THE PRIVATE SECTOR AND THE NHS AS WELL AS ACTING AS ONCODNA UK MEDIAL DIRECTOR COMMENTED: “In my view, this is an important first step in a collaboration that will make it much easier for public and privately practising oncologists to access biopsy tissue and request ONCODEEP* for the purpose of routine next generation sequencing. This unique public-private ...
By OncoDNA S.A.
-
OncoDNA Launches OncoDEEP® Kit for Comprehensive Biomarker Testing of Solid Tumors
UNIQUE WORKFLOW SOLUTION INTEGRATING A COMPRENSIVE PAN-CANCER NGS PANEL POWERED BY TWIST BIOSCIENCE AND A BIOINFORMATICS SOFTWARE SUITE ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, ANNOUNCED TODAY THE LAUNCH OF THE ONCODEEP KIT. THE KIT OFFERS A COMPLETE WORKFLOW SOLUTION WHICH ENABLES LABORATORIES WITH NGS ...
By OncoDNA S.A.
-
Autism Biomarkers Could Save Billions in Healthcare Costs According to Recent Study
The use of accurate biomarkers for detecting autism spectrum disorder (ASD) could result in saving billions of dollars in healthcare costs, according to a paper recently published in the journal Autism Research. Titled "Evidence–based Use of Scalable Biomarkers to Increase Diagnostic Efficiency and Decrease the Lifetime Costs of Autism," the paper showed that if more children with ASD are ...
-
OncoDNA Announces the Operational Launch of its OncoDEEP Kit for Comprehensive Genomic Profiling of Solid Tumors
A UNIQUE WORKFLOW SOLUTION INTEGRATING A PAN-CANCER NEXT-GENERATION SEQUENCING (NGS) PANEL POWERED BY A BIOINFORMATICS SOFTWARE SUITE FOR CUSTOMIZABLE BIOLOGICAL AND CLINICAL INTERPRETATION ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, TODAY ANNOUNCED THE OFFICIAL LAUNCH OF THE ONCODEEP KIT DURING THE ESMO ...
By OncoDNA S.A.
-
Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Chugai Pharmaceutical
Thermo Fisher Scientific has signed a companion diagnostic (CDx) agreement with Chugai Pharmaceutical Co., Ltd., a member of the Roche Group, and has applied to the Ministry of Health, Labour and Welfare (MHLW) to expand the use of the Oncomine Dx Target Test in Japan. The CDx will be leveraged to identify ROS1-positive non-small cell lung cancer (NSCLC) patients who may be eligible for treatment ...
-
FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) to identify RET fusion-positive, metastatic non-small cell lung cancer (NSCLC) patients who are candidates for GAVRETO™ (pralsetinib), a targeted therapy developed by Blueprint Medicines. The Oncomine Dx Target Test was initially ...
-
Thermo Fisher Scientific to Bring One-Day Genomic Profiling to Hematology Oncology
Clinical researchers who take a traditional sequential approach to analyze myeloid malignancies, a highly heterogeneous group of disorders, face a major hurdle: a laborious and time-consuming workflow. To simplify and accelerate the genomic profiling process, Thermo Fisher Scientific announced that the Ion Torrent Oncomine Myeloid Research Assay* will be available in 2020 to run on the newly ...
-
Pacific Edge Appoints Dr Peter Meintjes As Its New CEO
Pacific Edge today announces the appointment of Dr Peter Meintjes, an experienced molecular diagnostics and genomics business leader, as its new Chief Executive Officer. Dr Meintjes, a New Zealand citizen currently resident in Boston, brings to Pacific Edge extensive global diagnostics, biotechnology, and commercial leadership expertise. He also has a track record for commercialising new and ...
-
Bio-Techne’s Exosome Diagnostics Laboratory Announces Reimbursement Contract With Humana
Bio-Techne Corporation (NASDAQ:TECH) today announced that Humana has awarded a contract effective April 1, 2021 to its Exosome Diagnostics laboratory, covering the ExoDx™ Prostate (EPI) test for men. Humana is the nation’s largest Medicare Advantage provider serving an estimated 20 million patients in the United States. The EPI test is a urine-based, genomic test that helps inform ...
-
Stilla and Promega Announce Co-Marketing Agreement to Offer Complete Digital PCR Workflow Solution
Stilla Technologies, the multiplex digital PCR company, and Promega Corporation today announced a co-marketing agreement that combines sample preparation with the latest Maxwell® systems and digital PCR on the six-color naica® system. With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, ...
-
MiraDx Offering COVID-19 PCR Testing for California Skilled Nursing Facilities
LOS ANGELES--(BUSINESS WIRE)--MiraDx, a Los Angeles-based molecular genetics company that transitioned its CLIA-certified laboratory to provide COVID-19 PCR testing, is further expanding access to skilled nursing facilities (SNFs) in California. This will help these facilities provide fast and accurate COVID-19 testing for health care personnel and residents in accordance with recently released ...
By MiraDx
-
New Metabolic Biomarkers Open Door to Earlier Diagnosis, More Precise and Individualized Treatment of Children at Risk for Autism
Continued analysis of samples from the Children’s Autism Metabolome Project (CAMP), the most comprehensive clinical study of metabolism in children who have autism spectrum disorder (ASD) conducted to date, has identified three new areas of metabolism that affect the biology of children with ASD. These include biomarkers indicating that altered neurotransmission, energy metabolism, and ...
By NeuroPointDX
-
BioMark Receives Funding, Support, Research and Development Project for Cancer Treatment Monitoring
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to detect and treat ...
-
Alzheimer’s Drug Discovery Foundation’s diagnostics accelerator announces first digital biomarker research award and data sharing platform
Digital biomarker awards support technology solutions for early detection of Alzheimer’s and related dementias Data platform enables researchers using digital tools to share their findings for benchmarking, analysis and use across research projects ADDF’s Diagnostics Accelerator has $50 million in commitments from leading philanthropists Leonard A. Lauder, Bill Gates, Jeff Bezos ...
-
C2i Genomics Partners with OncoDNA to Bring AI-Powered Liquid Biopsy for Cancer Diagnostics Across Europe
C2i Genomics, a cancer intelligence company, today announced expansion into Europe through a strategic partnership with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases. With entities based in Belgium, France, Spain and the UK, OncoDNA has built an outstanding network of cancer clinicians-researchers ...
By OncoDNA S.A.
-
Cleveland Diagnostics Chief Medical Officer, Mark Stovsky, MD, Participates in Panel Discussion on Early Cancer Detection During Cleveland Clinic`s 2019 Medical Innovation Summit
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced that its chief medical officer, Mark Stovsky, MD, participated in an Impact Session at the 2019 Medical Innovation Summit organized by Cleveland Clinic. The Medical Innovation Summit, which is celebrating its 17th year, is covering a wide ...
-
DARPA Awards Inflammatix up to $1.1 Million to Develop Diagnostic that Predicts COVID-19 Severity Risk
Inflammatix a pioneering molecular diagnostics company, announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company up to $1.1 million for further development of a rapid diagnostic that reads the immune system to predict severe respiratory failure risk in COVID-19 patients. The diagnostic is being developed to help physicians make better hospital admission ...
-
Spatial Biology CRO Flagship Biosciences Acquires Pharma Services Business from Interpace Biosciences
Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma Solutions® (“IPS”), a division of Interpace Biosciences and provider of cytogenetic, molecular pathology, and genomic profiling solutions. This acquisition follows a growth equity investment in Flagship from Ampersand Capital Partners, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you